Pd46-12 preclinical studies using cisplatin/carboplatin to restore the enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (arv7) to further suppress enzalutamide resistant prostate cancer
Journal of Urology(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要